issued shares in Indo Rama Synthetics (India) Limited (“IRSL”), equaling to approximately 31.79% of IRSL’s enlarged share capital (the “Share Purchase”) at the price of INR 36 per share. The Company would

by its indirect subsidiary Indorama Netherlands B.V. (“INBV”) of 83,000,000 newly issued shares in Indo Rama Synthetics (India) Limited (“IRSL”), equaling to approximately 31.79% of IRSL’s enlarged

or 22.90% over the same period of last year of which hospital revenues totally raised by 10.16% along with the enlarged customer base of Subsidiary (AMARC) showing 15.67% of revenues’ growth. In

year, the Company has not yet earned income from Excellence Center (New Building) planned to official grand opening in the following year of February 2018) along with the enlarged customer base of the

301.92 Million Baht from 327.37 Million Baht or 7.77%, due to less or pending projects from oil and gas companies resulting from slowdown economy. 2. Our net loss before tax is 23.97 Million Baht

for two years. The later, on February 18, 2020, The Appeal Court reversed the judgment of the Criminal Court, not pending for punishment and not fines. The case was deemed final. On April 10, 2018, the

fine. The jail term was suspended for two years. The later, on February 18, 2020, The Appeal Court reversed the judgment of the Criminal Court, not pending for punishment and not fines. The case was

2,666,666.67 Baht fine. The jail term was suspended for two years. The later, on February 18, 2020, The Appeal Court reversed the judgment of the Criminal Court, not pending for punishment and not fines. The

(urgent case), effective since 11 March 2019. The SEC views that since IFEC Board of Directors is now eligible to form a quorum, the company should be able to proceed and seek solutions for the pending

turnkey projects, pending the full members of owner‘s acceptance committee in place for the final handover inspection, caused delays in revenue recognition to next quarters accordingly. Profit for the